The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2022 | Latest advances in BP-MPNs
Guillermo Ortí, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, gives an overview of the latest developments in blast phase myeloproliferative neoplasms (BP-MPNs). Dr Ortí mentions the recent introduction of venetoclax, as well as new combinations including ruxolitinib and hypomethylating agents (HMAs), and new data on allogeneic hematopoietic stem cell transplantation (alloHSCT) that will be presented at EBMT. These advances are expected to reduce the relapse risk and the transformation risk in this patient population. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
